Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis And China MOH Collaborate On Organ Donation Project

This article was originally published in PharmAsia News

Executive Summary

China's Ministry of Health's International Health Exchange and Cooperation Center and Novartis Foundation for People and the Environment have kicked off the second phase of China's first and largest collaborative international project on organ donation and transplant. The project, with a total funding of up to 20 billion yuan ($2.92 billion) will concentrate on organ transplant academic exchange, public education and publicity, a study on brain death, as well as R&D on living related transplantation. The Novartis foundation will invest 2 million Swiss francs in phase two of the project from 2008 to 2012. MOH will accelerate China's establishment of an organ transplant management system and seek out more international organizations and relevant parties to develop the program. (Click here for more - Chinese Language)

You may also be interested in...

China's Organ Donation System Overhauled

China's organ donation and transplant program will provide a platform for facilitating technology transfer and enhancing the establishment of the China Organ Donor System. The collaborative project between the Ministry of Health and Novartis was launched in 2003 to promote organ donation and transplant development in China (PharmAsia News, July 21, 2008). Last month, the program actively supported the Organ Transplantation Committee's meeting on organ donation mobilization, CODS establishment and trial initiation. A recent organ donation and transplant seminar discussed supplementary clauses for regulations on human organ transplantation; the program will strengthen live organ transplant standardization and set up an organ transplant data center. (Click here for more - Chinese Language)

What COVID Spotlight Means For Pharma – In Their Own Words

Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem. 

Deal Watch: Bristol Teams Up With Insitro, Sensyne In AI-Directed Collaborations

Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts